JULY 23, 2021 | EYEWORLD DAILY NEWS | 23
IHEEZO, IHEEZO logo, Harrow and the Harrow logo are trademarks of Harrow IP, LLC.
©2023 Harrow. All rights reserved.
IZO-00050 04/23
References: 1. Iheezo. Prescribing information. Harrow IP, LLC; 2022. 2. Data on File. Harrow IP, LLC; 2023.
APPROVED USE
IHEEZO is indicated for ocular surface anesthesia.
IMPORTANT SAFETY INFORMATION
IHEEZO is contraindicated in patients with a history of hypersensitivity to any component of this preparation.
IHEEZO should not be injected or intraocularly administered.
Patients should not touch the eye for at least 10 to 20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye.
Prolonged use of a topical ocular anesthetic may produce permanent corneal opacification and ulceration with accompanying visual loss.
Do not touch the dropper tip to any surface as this may contaminate the gel.
IHEEZO is indicated for administration under the direct supervision of a healthcare provider. IHEEZO is not intended for patient
self-administration.
The most common adverse reactions in studies following IHEEZO administration (incidence greater than or equal to 5%)
were mydriasis, conjunctival hyperemia, and eye irritation.
You are encouraged to report suspected adverse reactions to the FDA. Visit www.fda.gov/medwatch,
or call 1-800-FDA-1088.
Please see Brief Summary of Full Prescribing Information for IHEEZO on adjacent page.
* In the clinical trial, no patient undergoing routine cataract surgery receiving IHEEZO required supplemental treatment to maintain anesthesia; this was not the case for patients receiving tetracaine.
Supplemental treatment was defined as general anesthesia, intraoperative systemic analgesia, or local anesthesia. Though supplemental administration was not required by any patient in the clinical
trial, IHEEZO may be reapplied as needed to maintain anesthesia.
1,2
†
Sufficient anesthesia with IHEEZO lasted an average of 21.5 minutes in the clinical trial, while mean total surgical time was 13.9 minutes.
2
patients reported
experiencing pain
2
serious adverse events
with an established
safety profile
2
supplemental treatment
needed to maintain
anesthesia*
†1
In
a
Phase
III
clinical
study
of
IHEEZO,
IHEEZO™ is the topical ocular anesthetic that compromises on
nothing. Rapid onset and an established safety profile for your
patients. No uncertainty with a sterile, single-use unit for you.
Visit IHEEZO.com to learn more.
IHEEZO Gives
You Nothing
Unique J-Code J-2403 Helps Facilitate Reimbursement
